Summary Lometrexol (5,10-dideazatetrahydrofolic acid; DDATHF), is a specific inhibitor of glycinamideribonucleosyl (GAR) transformylase with anti-tumour activity in murine and human carcinomas. The cytotoxicity activity of DDATHF was evaluated in vitro in NIH/3T3 cells transfected with human a-folatebinding protein (FBP) 
5,10-Didzatetrahydrofolic acid (DDATHF, Lometrexol) is representative of a new class of antimetabolites designed to inhibit folate-dependent enzymes other than dihydrofolate reductase. Its mode of action is related to the inhibition of glycinamideribonucleosyl (GAR) transformylase, a key enzyme in the de novo synthesis of purines (Moran et al., 1985; Beardsley et al., 1989; Taylor et al., 1989; Baldwin et al., 1991) and it is under early clinical investigation in Europe and in the USA (Muggia et al., 1990; Sessa et al., 1990; Young et al., 1990; Ray et al., 1993; Humphreys et al., 1995) .
Aspects of the cellular pharmacology of DDATHF have been investigated in detail; it causes no detectable DNA breaks even after 48 h continuous exposure and its cytotoxic potential can be modulated by folic and folinic acid (Erba et al., 1994) ; DDATHF prevents the proliferation of tumour cells in vitro Beardsley et al., 1989; Moran et al., 1989; Erba et al., 1994) and in vivo (Beardsley et al., 1986; Shih et al., 1988; Alati et al., 1992; Grindley et al., 1992) , and causes purine nucleotide depletion . Because of its chemical homology to folates, the drug is taken up by cells through physiological folate uptake mechanisms (reviewed in Antony, 1992) .
One of the major uptake systems utilised by eukaryotic cells is the high-affinity folate receptor called folate-binding protein (FBP) . FBP is a family of related genes expressed at different levels in different tissues (Ross et al., 1994; Sadasivan et al., 1994) . Three FBP isoforms have been identified at the molecular level: (1) the a-isoform, which is expressed at low levels in a few normal tissues and tends to be elevated in some malignant tissues of epithelial origin; (2) the 13-isoform, which is expressed at low to moderate levels in all normal tissues and elevated in malignancies of nonepithelial origin; and (3) the recently identified y-isoform, which is present in certain carcinomas and in normal and malignant hematopoietic cells. Ovarian carcinoma cells in particular show a several-fold increase in a-FBP expression. Therefore, this oncotype could be considered a prime target for DDATHF therapy. The following human ovarian carcinoma cell lines were used: IGROVI (Benard et al., 1985) , SKOV3 (Fogh et al., 1977) , OVCAR3 (Hamilton et al., 1983) and SW626 (Fogh et al., 1977) . These cells were grown as monolayers in RPMI supplemented with 10% dialysed FBS or in custom-prepared folic acid-free medium supplemented with 10% dialysed FBS.
All the cell lines were routinely checked for mycoplasma contamination following the American Type Culture Collection protocol and found to be negative. , 150 mM sodium chloride, 5 mM EDTA, 1.1% n-octylglucoside, 0.24 TIU ml-' aprotonin, 1% phenlymethylsulphonyl fluoride (PMSF)] at 5 x 106 cells ml-'. Samples were centrifuged for 10 min at 11 000 g and supernatants recovered. To eliminate endogenous folate cell lysates were treated for 30 min on ice with 100 mM acetic acid (pH 3) in 0.9% sodium chloride and centrifuged for 5 min at 1600 g on a Sephadex G-25 microcolumn (0.9 ml bed volume) equilibrated in lysis buffer containing 0.25% gelatin. Soluble extracts were incubated with [3H]folic acid overnight at room temperature and then applied to a spin column prepared as described above. The eluted fractions were assessed for radioactivity. Protein concentration was determined according to Bradford (1976 al., 1993) . In FBP-tNIH/3T3 cells, ax-FBP expression was about 30 times higher than in mock t-NIH/3T3 cells growing in DMEM and the receptor actively internalised 5-MTHF (Table I) . When these cells were conditioned to grow in DMEM without folic acid, FBP content, evaluated by MOv 18 binding, remained unchanged, cell growth was slightly retarded but cell morphology was unaltered.
The cytotoxic. activity of DDATHF was investigated on FBP-t and mock-tNIH/3T3 cells to examine the possible role of the receptor. Cells grown in DMEM were conditioned to grow in low-folate media by reducing the folic acid concentration from 9.2 pM to 0.9 pM for at least six Table II ).
DDATHF cytotoxicity on FBP-stripped ovarian cancer cells To confirm that FBP was responsible for DDATHF internalisation an experiment was designed to compare drug cytotoxicity in the same cell line after removal of FBP from the membrane. IGROVI cells grown in folic acid-free RPMI, in which the cytotoxic potential of DDATHF was greatly increased (Figure 2 ), were treated with PI-PLC, to which the FBP of these cells is highly sensitive (Miotti et al., 1992) . Figure 3 shows that a 2 h digestion with PI-PLC reduced FBP expression to near-negative control levels. At 4 h of recovery (histogram C), cells began to express FBP again. After 24 h (histogram D), FBP expression had increased significantly but some of the cells were still negative. We then did a 4 h DDATHF treatment immediately after PI-PLC digestion on FBP-stripped IGROVI growing in folic acid-free RPMI (Figure 4) . The cytotoxic potential of DDATHF was not detectable, even at the maximal dose tested in IGROVI 
Discussion
The present study shows that FBP plays an important role in the cytotoxicity of DDATHF since NIH/3T3 cells transfected with a-FBP cDNA become approximately 10-fold more sensitive to the drug than the mock-tNIH/3T3 cells when grown in medium with low folic acid content. DDATHF has been reported to use both the classical reduced folate carrier and FBP Westerhof et al., 1991; Pizzorno et al., 1993) . In FBP-tNIH/3T3 cells folic acid acts as a tight binding inhibitor of receptor-coupled processes and in folic acid-free DMEM the cytotoxic potential of DDATHF was observed only at concentrations higher than 500 nM. On the other hand, in medium without folic acid only FBP-tNIH/ 3T3 cells were sensitive at 10 nM of the drug. Since FBP appears to be highly expressed in human ovarian cancer, it was of interest to investigate the cytotoxicity of DDATHF in cells derived from this type of tumour and to evaluate whether the modulation of the expression of FBP modified the drug cytotoxicity in these cell lines.
In two out of four cell lines, OVCAR3 and IGROVI, the low concentration of folic acid did not induce any relevant change in FBP expression determined either using MOv18 and MOvl9 antibody or as folic acid binding. However, under those conditions, there was an increase in DDATHF cytotoxicity in both cell lines, suggesting that folic acid bound to FBP reduces the anti-tumour activity of the drug. These data are consistent with earlier observations that the presence of folic acid and folinic acid markedly reduce the cytotoxicity of DDATHF in vitro (Erba et al., 1994) , and in vivo the toxicity was reversed and DDATHF anti-tumour activity retained only in animals that had received folic acid before DDATHF Grindey et al., 1992) .
In Since it is well known that the reduced folate carrier is a transmembrane glycoprotein not sensitive to PI -PLC treatment, we suggest that the major protein involved is the FBP.
Together these studies, particularly those comparing mock and mFBP transfected NIH/3T3 cells and on IGROVI stripped of membrane FBP, indicate the importance of mFBP for the cytotoxicity of DDATHF. However, the data obtained in the four ovarian cancer cell lines suggest that other factors are implicated too, as there was no correlation between the levels of FBP and the ICso. Because no radiolabelled DDATHF of high specific activity was available, it was not possible to measure intracellular DDATHF uptake. Therefore, one of the possibilities is that the different cytotoxicity is, at least in part, related to different efficiency of the reduced folate carrier.
Analysis of 5-MTHF internalisation in the present cell lines, as well as in other ovarian carcinoma cell lines, indicates that FBP is not functional in some of them (S Miotti, personal communication) and that the expression of the reduced folate carrier remains unaltered in folate-depleted medium.
A further important cellular determinant of DDATHF cytotoxicity is accumulation of the polyglutamate forms of the drug, which is related to the activity of folylpolyglutamate syntethase, together with altered reduced folate pools and increaed y-glutamyl hydrolase activity (Pizzorno et al., 1995) . Polyglutamylated derivatives of DDATHF are not only retained longer in cells but are also much more potent inhibitors of GAR transformylase which is the main biochemical target of this antifolate Pizzorno et al., 1991) .
In conclusion, although FBP expression appears to be an important factor for the cytotoxicity of DDATHF, the data obtained in these ovarian cancer cell lines suggest that FBP in human tumours cannot be considered a sufficiently reliable predictor of the sensitivity to DDATHF. Thus, FBP cannot be the only parameter used for the selection of potentially responsive patients to antifolate drugs. 
